Stay updated with breaking news from Human Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
EFFISAYIL™ 2 met its primary and key secondary endpoint, demonstrating that spesolimab, an anti-interleukin-36 receptor antibody, can prevent flares in adolescents and adults with generalized pustular psoriasis (GPP) up to 48 weeks.1,2
The Top Employers Institute, a global authority that recognises excellence in people practices, has awarded Boehringer Ingelheim ‘Global Top Employer’ for the third consecutive year.
Ruth Lütticken, Director of Life Sciences, Data Science & AI, Capgemini, explains how data management is helping Boehringer Ingelheim to transform lives
-- Boehringer Ingelheim Thailand Honored As Top Employer For The Fifth Consecutive Year
/PRNewswire/ -- Boehringer Ingelheim Indonesia Honored As Top Employer For The Fourth Consecutive Year